CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells.

Abstract

Osteosarcoma is the most common primary malignant tumor, and its treatments require more effective therapeutic approaches. Paclitaxel has a broad range of antitumor activities, including apoptosis-inducing effects. However, the majority of tumors in patients with advanced cancer eventually develop chemoresistance. Connective tissue growth factor (CTGF) is a… (More)
DOI: 10.1016/j.bbamcr.2014.01.007

5 Figures and Tables

Topics

Statistics

0102030201520162017
Citations per Year

Citation Velocity: 8

Averaging 8 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.
  • Presentations referencing similar topics